ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Ionis and Roche sign antisense pact

by Ryan Cross
October 13, 2018 | APPEARED IN VOLUME 96, ISSUE 41

Roche is teaming up with the antisense oligonucleotide company Ionis Pharmaceuticals to advance a treatment for dry age-related macular degeneration. Ionis has already completed a Phase I study and will begin a Phase II study in early 2019 with a fresh $75 million in up-front payments from Roche. If Roche likes the results, it may acquire the experimental treatment, and Ionis could earn up to $684 million in milestone payments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment